EU Launches Antitrust Probe Over Lundbeck Drug

Law360, New York (January 07, 2010, 2:01 PM ET) -- The European Commission has opened a formal antitrust investigation into Danish drugmaker H. Lundbeck A/S, principally examining whether the company has restricted the entry of a generic version of its antidepressant drug citalopram.

The EC said Thursday that it intends to probe whether agreements the company made have blocked generic rivals from producing their own versions of citalopram. The Commission said the formal investigation of Lundbeck was prompted by knowledge acquired during the regulator's recent inquiry into the pharmaceutical sector, particularly related to ways branded drug...
To view the full article, take a free trial now.
Try Law360 for free for seven days
Already a subscriber? Click here to login

Already have access?

  1. Forgot your password?
  2. Sign In

Get instant access to the one-stop news source for business lawyers

Required